GlassScriptPhysician profile
Jeffrey Cobb
NPI 1376028167
$8,478.62
in general payments reported to CMS, 2019-2025
35 companies · $2,315 in 2025
The $2,315 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,369 · 2022: $1,039 · 2023: $1,778 · 2024: $1,978 · 2025: $2,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,933 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,933.05 |
| Education | $138.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,100.67 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,200.65 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $809.26 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $629.49 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $503.80 | 2021-2025 | |
| Ardelyx, INC. | $407.89 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $336.19 | 2021-2024 | Dificid |
| Genzyme Corporation | $320.90 | 2023-2025 | |
| Lilly USA, LLC | $255.52 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $234.77 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $215.72 | 2024-2025 | Vowst, Zenpep |
| Pfizer INC. | $203.13 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $138.82 | 2021-2024 | Linzess |
| Madrigal Pharmaceuticals | $129.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $112.55 | 2022-2024 | Rebyota, Cimzia, Clenpiq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $101.52 | 2025 | Sucraid |
| Organon LLC | $81.27 | 2021-2025 | Hadlima |
| Alnylam Pharmaceuticals INC. | $71.84 | 2023 | Givlaari |
| Nestle Healthcare Nutrition INC. | $69.28 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $57.34 | 2024 | Dojolvi |
| Regeneron Healthcare Solutions, INC. | $54.15 | 2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $48.48 | 2025 | Iqirvo |
| Amgen INC. | $47.99 | 2021-2022 | |
| Boston Scientific Corporation | $42.88 | 2025 | Watchman Flx |
| Fresenius Kabi USA, LLC | $41.96 | 2023-2024 | Idacio |
| Braintree Laboratories, INC. | $40.84 | 2024-2025 | Sutab, Suflave |
| Celltrion USA INC. | $38.42 | 2023-2024 | Zymfentra, Yuflyma |
| Sandoz INC. | $36.82 | 2024-2025 | |
| Celgene Corporation | $35.34 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $32.55 | 2023-2024 | Ocaliva |
| Sanofi-Aventis U.S. LLC | $22.65 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.38 | 2024 | |
| Lucid Diagnostics INC. | $19.39 | 2024 | |
| Redhill Biopharma INC. | $13.77 | 2021 | |
| Janssen Scientific Affairs, LLC | $3.15 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.